Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

View from City Road: SmithKline forges a promising link-up

Thursday 20 May 1993 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Hillary Clinton is nothing compared with human genes when it comes to introducing uncertainty into the longer-term prospects for individual drug stocks. Her putative reforms of America's healthcare system may take an axe to the prices of some of their existing medicines. But genetic research offers the tantalising possibility of products that could eclipse losses a hundredfold.

Try asking any of the world's 500 million smokers how much they would be prepared to pay for a test to discover if they were genetically pre- disposed to getting cancer from their habit. Small wonder this is an area all the big drug companies are pre- disposed to be in.

These are muddy enough waters for scientists, let alone investors, however. The word 'biotech' has long been an excuse for stratospheric share prices.

SmithKline Beecham's new strategic alliance with the US-based Human Genome Sciences, under which it will get worldwide rights to products developed by HGS from data on gene sequencing - the process of identifying the role played by genes in disease - could, however, be more significant than most.

HGS was created in 1992 by the Healthcare Investment Corporation, a venture capital fund. Two years ago the same fund provided Craig Venter, one of the key scientists in this area, with more than dollars 70m to set up the Institute for Genomic Research.

As part of the deal with HIC, he has agreed to allow Human Genome Sciences to commercialise the institute's health care applications.

Genetic research is moving on much faster than anyone expected, but finding a marketable product is likely to remain a lottery for some time to come. In linking up with HGS, however, SmithKline has increased its odds of a win.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in